234 related articles for article (PubMed ID: 9486679)
41. Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation.
Kaidbey K; Owens M; Liberda M; Smith M
Toxicology; 2002 Sep; 178(2):175-82. PubMed ID: 12160622
[TBL] [Abstract][Full Text] [Related]
42. Imiquimod; an international update on therapeutic uses in dermatology.
Tyring S; Conant M; Marini M; Van Der Meijden W; Washenik K
Int J Dermatol; 2002 Nov; 41(11):810-6. PubMed ID: 12453012
[TBL] [Abstract][Full Text] [Related]
43. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies.
Baker DA; Ferris DG; Martens MG; Fife KH; Tyring SK; Edwards L; Nelson A; Ault K; Trofatter KF; Liu T; Levy S; Wu J
Infect Dis Obstet Gynecol; 2011; 2011():806105. PubMed ID: 21876641
[TBL] [Abstract][Full Text] [Related]
44. Treatment of anogenital warts.
Maw RD
Dermatol Clin; 1998 Oct; 16(4):829-34, xv. PubMed ID: 9891689
[TBL] [Abstract][Full Text] [Related]
45. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women. A placebo-controlled, double-blind study.
Syed TA; Lundin S; Ahmad SA
Dermatology; 1994; 189(2):142-5. PubMed ID: 8075441
[TBL] [Abstract][Full Text] [Related]
46. Anecdotal reports of 3 cases illustrating a spectrum of resistant common warts treated with cryotherapy followed by topical imiquimod and salicylic acid.
Housman TS; Jorizzo JL
J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S217-20. PubMed ID: 12271281
[TBL] [Abstract][Full Text] [Related]
47. Imiqimod in clinical practice.
Trofatter KF
Eur J Dermatol; 1998; 8(7 Suppl):17-9; discussion 20-2. PubMed ID: 10387959
[TBL] [Abstract][Full Text] [Related]
48. Imiquimod therapy for molluscum contagiosum.
Liota E; Smith KJ; Buckley R; Menon P; Skelton H
J Cutan Med Surg; 2000 Apr; 4(2):76-82. PubMed ID: 11179929
[TBL] [Abstract][Full Text] [Related]
49. [Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions].
Gross G
Hautarzt; 2001 Jan; 52(1):6-17. PubMed ID: 11220242
[TBL] [Abstract][Full Text] [Related]
50. [Imiquimod--clinical efficacy].
Beutner KR
Ann Dermatol Venereol; 2000; 127(10 Suppl):3S19-3S21. PubMed ID: 11116859
[No Abstract] [Full Text] [Related]
51. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream.
Beutner KR; Geisse JK; Helman D; Fox TL; Ginkel A; Owens ML
J Am Acad Dermatol; 1999 Dec; 41(6):1002-7. PubMed ID: 10570388
[TBL] [Abstract][Full Text] [Related]
52. Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology.
Berman B
Int J Dermatol; 2002 May; 41 Suppl 1():7-11. PubMed ID: 12087816
[No Abstract] [Full Text] [Related]
53. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study.
Syed TA; Goswami J; Ahmadpour OA; Ahmad SA
J Dermatol; 1998 May; 25(5):309-13. PubMed ID: 9640884
[TBL] [Abstract][Full Text] [Related]
54. Imiquimod: an immune response modifier.
Dahl MV
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S1-5. PubMed ID: 10861100
[No Abstract] [Full Text] [Related]
55. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream.
Cowen E; Mercurio MG; Gaspari AA
J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S240-8. PubMed ID: 12271286
[TBL] [Abstract][Full Text] [Related]
56. Imiquimod cream in the treatment of actinic keratoses.
Persaud A; Lebwohl M
J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S236-9. PubMed ID: 12271285
[TBL] [Abstract][Full Text] [Related]
57. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.
Harrison CJ; Miller RL; Bernstein DI
Vaccine; 2001 Feb; 19(13-14):1820-6. PubMed ID: 11166907
[TBL] [Abstract][Full Text] [Related]
58. Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.
Arany I; Tyring SK; Brysk MM; Stanley MA; Tomai MA; Miller RL; Smith MH; McDermott DJ; Slade HB
Antimicrob Agents Chemother; 2000 Jul; 44(7):1869-73. PubMed ID: 10858346
[TBL] [Abstract][Full Text] [Related]
59. Imiquimod 5% cream: a topical immune response modifier.
Marini M
Int J Dermatol; 2002 May; 41 Suppl 1():1-2. PubMed ID: 12087812
[No Abstract] [Full Text] [Related]
60. Immunomodulatory and pharmacologic properties of imiquimod.
Sauder DN
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S6-11. PubMed ID: 10861101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
